ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical practice guidelines"

  • Abstract Number: 2017 • ACR Convergence 2024

    Race, Ethnicity, and Rheumatology Care Predict Long-term Urate-Lowering Treatment Persistence Following a Treat-to-Target Intervention in a Large, Multicenter Randomized Trial

    Samantha Kohn1, Harlan Sayles1, Lindsay Helget1, Bryant England1, Punyasha Roul2, Joshua Qu1, Jeff Newcomb1, Bridget Kramer1, Michael Duryee1, Anne Davis-Karim3, Mary Brophy4, Ryan Ferguson4, Michael Pillinger5, Tuhina Neogi6, Paul Palevsky7, Hongsheng Wu4, James O'Dell1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3Veterans Affairs, Albuquerque, NM, 4Veterans Affairs, Boston, MA, 5New York University Grossman School of Medicine, New York,, NY, 6Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 7Veterans Affairs, Pittsburgh, PA

    Background/Purpose: Gout management guidelines endorse treat-to-target (T2T) urate lowering therapy (ULT) to achieve and maintain serum urate (sUA) < 6.0 mg/dl. While T2T ULT interventions…
  • Abstract Number: 2162 • ACR Convergence 2024

    Exploring Barriers to Rheumatoid Arthritis Treatment Changes: Insights into Patient Concerns

    Nicholas McCormick1, Jeffrey Curtis2, Amy Mudano3, Shilpa Venkatachalam4, Kelly Gavigan5, Fenglong xie6, Patrick Stewart7 and Kimberly Garza1, 1Auburn University, Auburn, AL, 2Illumination Health, Birmingham, AL, 3Illumination Health, Hoover, AL, 4Global Healthy Living Foundation, New York, NY, 5Global Healthy Living Foundation, Upper Nyack, NY, 6University of Alabama at Birmingham; Illumination Health, Birmingham, AL, 7Illumination Health, Vero Beach, AL

    Background/Purpose: People with rheumatoid arthritis (RA) often hesitate to adjust their treatment due to concerns about medication risks and benefits. This study investigates RA patients'…
  • Abstract Number: 2304 • ACR Convergence 2024

    Differential Diagnosis of Sjogren’s vs Non-Sjogren’s Dry Eye

    Esen Akpek1, Ian Saldanha2, Pineal Bareamichael2 and Michael Lin3, 1Wilmer Eye Institute, JHU, Baltimore, MD, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Dry Eye Disease (DED) is a common multifactorial condition that significantly impacts patient quality of life. The etiology of DED is complex, involving tear…
  • Abstract Number: 2409 • ACR Convergence 2024

    Adherence to EULAR Recommendations and Sub Optimal Management of Systemic Lupus Erythematosus in a Network of Community-Based Rheumatology Practices in the United States

    Jeffrey Curtis1, Emily Holladay2, Amy Mudano3, Emily Smitherman4, Fenglong xie5, Shanette G. Daigle6, Yujie Su3, Mawuena Binka7, Gelareh Atefi8, Rana Muhammad Qasim Khan9 and Tope Olufade10, 1Illumination Health, Birmingham, AL, 2University of Alabama at Birmingham, Edmond, OK, 3Illumination Health, Hoover, AL, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham; Illumination Health, Birmingham, AL, 6Foundation for Advancing Science, Technology, Education, and Research, Birmingham, 7BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 8AstraZeneca, Media, PA, 9BioPharmaceuticals Medical, AstraZeneca, Wilmington, 10AstraZeneca, Wilmington, DE

    Background/Purpose: Despite new developments in systemic lupus erythematosus (SLE) treatment and treatment guidelines, the clinical management of SLE is often sub-optimal. We aimed to describe…
  • Abstract Number: 0214 • ACR Convergence 2024

    Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Justin Dunn1, Scott Matson2, Michael George3, Yangyuna Yang1, Punyasha Roul4, Jorge Rojas5, grant Cannon6, Sauer brian7, Jeffrey Curtis8, Joshua Baker3, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Kansas, Kansas City, MO, 3University of Pennsylvania, Philadelphia, PA, 4UNMC, Omaha, NE, 5Seattle VA, Mexico, Mexico, 6University of Utah and Salt Lake City VA, Salt Lake City, UT, 7Salt Lake City VA/University of Utah, Salt Lake City, UT, 8University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: The American College of Rheumatology (ACR) and American College of Chest Physicians (CHEST) recently released clinical practice guidelines for the treatment of RA-interstitial lung…
  • Abstract Number: 2619 • ACR Convergence 2024

    Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients

    Tali Eviatar1, Iftach Sagy2, Elad Brav2, Amir Bieber3, Victoria Furer4 and Ori Elkayam5, 1Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, 2Soroka Medical Cenrter, beer sheva, Israel, 3Emek Medical Center, Clalit Health Services, Raanana, Israel, 4Tel Aviv Medical Center, Tel Aviv, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
  • Abstract Number: 0537 • ACR Convergence 2024

    Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk

    Knkush Hakobyan1, Talar Acob2, Mesrop Aleksanyan3, Tigran Kakhktsyan3, Omar Jumaah3 and Sajina Prabhakaran4, 1Capital Health medical center, Princeton, NJ, 2College of medicine-university of Baghdad, Plainsboro Township, NJ, 3Capital Health Medical Center, Trenton, 4Capital health Rheumatology specialists, Newtown, PA

    Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…
  • Abstract Number: 2687 • ACR Convergence 2024

    Therapeutic Choices in Systemic Sclerosis Associated Interstitial Lung Disease, a Survey of International Experts

    Michael Macklin1, Iazsmin Bauer Ventura1 and Dinesh Khanna2, 1University of Chicago, Chicago, IL, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: The therapeutic options for systemic sclerosis-associated interstitial lung disease (SSc-ILD) have evolved rapidly, with recent guidelines released by the ACR and American Thoracic Society…
  • Abstract Number: 0657 • ACR Convergence 2024

    Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis

    Jagan K L1, Augustine Jose2, Vishnupriya G1, Dellan S1, Dhanush S1, Samskruthi Reddy Tokala1, Bhavana Mashetty1, Chengappa Kavadichanda3, Sachith ganapathy1, Aishwarya Gopal4, Rithik Roshan1, Sareddy Sai vignesh Reddy1, Sonal Mehra5, Molly Thabah1 and Vir Singh Negi6, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 2Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, 4Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, 5JAYPEE HOSPITAL, Noida, Uttar Pradesh, India, 6AIIMS, Bilaspur, Puducherry, Puducherry, India

    Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…
  • Abstract Number: 0692 • ACR Convergence 2024

    Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis

    Miriam Retuerto Guerrero1, Clara Moriano2, cristiana sieiro santos3, Laura Sierra Herranz4, Javier Juan Garcia4, Ivan Castellvi Barranco5 and elvira Diez álvarez4, 1Complejo Asistencial Universitario de León, Leon, Spain, 2Hospital León, LEON, Spain, 3Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, 4Complejo Asistencial Universitario de Leon, Leon, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is one of the leading causes of morbidity and mortality. Recently,…
  • Abstract Number: 0859 • ACR Convergence 2024

    Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

    Kylie Carlson1, Mahmut Kaymakci2, Sebastian E. Sattui3 and Michael Putman4, 1Medical College of Wisconsin, Milwaukee, WI, 2Mayo Clinic, Rochester, MN, 3University of Pittsburgh, Pittsburgh, PA, 4The Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Patients with polymyalgia rheumatica (PMR) may develop overt giant cell arteritis (GCA), but “subclinical” large vessel inflammation has also been reported in patients with…
  • Abstract Number: 1075 • ACR Convergence 2024

    Optimizing Herpes Zoster Vaccination in Rheumatoid Arthritis Patients Ages 18-49 Years: A Quality Improvement Approach

    Akhil Sood1, Pegah Jahangiri1, Christy Bill2 and Janice Lin1, 1Stanford University, Palo Alto, CA, 2Stanford Health Care, Palo Alto, CA

    Background/Purpose: Patients with rheumatoid arthritis are at increased risk for Herpes Zoster (HZ) infection, which is associated with increased hospitalizations and healthcare resource utilization. Despite…
  • Abstract Number: 1076 • ACR Convergence 2024

    Assessing the Reliability of ChatGPT on Recombinant Zoster Vaccination for Patients with Rheumatic and Musculoskeletal Diseases

    Akhil Sood, Pegah Jahangiri, Amanda Moyer and Janice Lin, Stanford University, Palo Alto, CA

    Background/Purpose: As artificial intelligence (AI) platforms continue to evolve, large language models (LLMs) such as ChatGPT by OpenAI are increasingly being utilized by patients and…
  • Abstract Number: 1173 • ACR Convergence 2024

    Safety of Non-Exercise Rehabilitation Interventions for Adults with Rheumatoid Arthritis

    Megna Mishra1, Joshua Torrey2, Bria Dunn2 and Louise Thoma3, 1UNC Health, Cary, 2University of North Carolina-Chapel Hill, Chapel Hill, 3University of North Carolina, Chapel Hill, NC

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory condition. Improved outcomes occur with early diagnosis, evaluation, and management. Management includes pharmacological, exercise, rehabilitation, diet,…
  • Abstract Number: 1402 • ACR Convergence 2024

    Addressing Unmet Needs in Cannabis and Hemp by Improving Knowledge and Data Collection

    Jahan Marcu1, Philip Molloy2, Kayla Pray3 and Teresa Simon4, 1Marcu Enterprises/ Physicians Research Center, Jersey City, NJ, 2Physicians Research Center,LLC, Carver, MA, 3Physicians Research Center,LLC, Farmingdale, NJ, 4Physicians Research Center,LLC, Toms River, NJ

    Background/Purpose: Cannabis and its derivatives are increasingly integrated into treatments for rheumatic diseases, yet there is a significant lack of evidence and systematic data collection…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology